An Analysis of the Long-Term Safety Data of Repeat Administrations of Botulinum Neurotoxin Type A-ABO for the Treatment of Glabellar Lines

Multiple cycles with fixed or variable dosing of BoNTA-ABO are well tolerated. There was no evidence of cumulative safety issues because the incidence of AE remained relatively constant or decreased over repeated treatment cycles.